



**Date: 06 February 2026**

<b>To</b> <b>BSE Limited</b> <b>Phiroze Jeejeebhoy Towers</b> <b>Dalal Street</b> <b>Mumbai – 400001</b>	<b>To</b> <b>National Stock Exchange of India Limited</b> <b>Exchange Plaza</b> <b>Bandra Kurla Complex, Bandra (E)</b> <b>Mumbai – 400051</b>
<b>Security Code: 540596</b>	<b>Security Code: ERIS</b>

**SUBJECT: BOARD MEETING INTIMATION**

Dear Sir/Madam,

**NOTICE IS HEREBY** given that a Meeting of the Board of Directors of **Eris Lifesciences Limited** (“the Company”) is scheduled on Friday, February 13, 2026, to, inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.

Further, as informed by us vide letter dated December 29, 2025, the trading window has been already closed from January 01, 2026, and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015, and Policy on ‘Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company’.

Thanking You,

**For Eris Lifesciences Limited**

\_\_\_\_\_  
**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**  
**ICSI Mem. No: A26493**

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867